MENU

Can Humana (HUM) Stock Reach $465?

a company offers health insurance coverage and related services

A.I.Advisor
published price charts
A.I.Advisor
Nov 02, 2026

Can Humana (HUM) Stock Reach $465?

Key Takeaways

  • The central target of $465 is the arithmetic mean of roughly two dozen verified analyst price targets, spanning a wide range from about $280 to $596.
  • With the latest close near $414.50, reaching $465 implies roughly 12% upside — a modest move by historical standards.
  • The consensus rating is a Buy, but dispersion is unusually wide: cautious Hold and Sell views sit at the low end while several Buy-rated firms target $500 or more.
  • The strongest support is Humana's 2027 Medicare Advantage Star Ratings recovery, with 95% of members in 4-star-or-higher plans, reinstating quality bonus revenue.
  • The biggest risks are margin-execution uncertainty, regulatory and coding scrutiny, an above-peer valuation, and a planned exit of roughly 600,000 lower-return members.
  • Fiscal 2026 EPS (earnings per share) guidance is maintained at a $9 floor, near the roughly $9.16 consensus; third-quarter results are due November 6, 2026.
  • For more detail, explore Humana's Major News, Today's Price Move, Forecast, and Earnings pages.
  • For AI-driven market insights, explore Trending AI Robots.

Analyst Price Targets and Consensus View

Humana Inc. (HUM) is one of the most debated names in managed care, and its analyst price targets reflect that divide. Recent individual targets include $596 at Robert W. Baird, $582 at Barclays, $525 at Oppenheimer, $520 at Raymond James, $495 at both Mizuho and UBS, $480 at Evercore ISI, $475 at Truist, $471 at Guggenheim, and $460 at Cantor Fitzgerald. The low end of the current range sits near $280, producing an unusually wide $280-to-$596 spread.

Averaging the roughly two dozen current targets yields a figure near $465, the rounded central target used here. That is consistent with independent aggregations — S&P Global's 26-analyst average of about $465 and Barron's figure near $460 — though it should not be read as a guarantee. Analysts cluster around a "Buy" stance, but the gap between the cautious and bullish camps is driven by differing assumptions about how quickly Medicare Advantage margins recover and whether the valuation premium can be sustained.

Current Market Position and Path Toward the Target

Humana closed near $414.50 on October 30, 2026, toward the upper end of a 52-week range of $163.11 to $456.50 after a powerful run. Moving to $465 requires about 12% upside — a modest advance by equity standards but one that would take the stock above its prior high and into new territory.

The path hinges on execution rather than multiple expansion alone. Humana trades at a forward P/E (price-to-earnings ratio) well above large managed-care peers, so further gains would most plausibly come from evidence that its multiyear Medicare Advantage margin-restoration plan — targeting at least a 3% pretax margin by 2028 — is tracking ahead of schedule, alongside continued Star Ratings momentum and cost discipline in its CenterWell care-delivery segment.

What Could Support a Move Toward the Target

  • Star Ratings recovery: Humana's 2027 ratings show 95% of members in 4-star-plus plans, up sharply from 41% in 2026, restoring access to federal quality bonus payments. The company projects 2027 star revenue near $160 per member per month, above its top-quartile target.
  • Margin restoration plan: Disciplined 2027 bids and exits from roughly 600,000 lower-return members are designed to rebuild profitability over several years.
  • CenterWell restructuring: A new joint venture with BlackRock (HPS Investment Partners) to manage CenterWell Senior Primary Care clinics reduces capital intensity and refocuses the portfolio.
  • Analyst revisions: A wave of upgrades and target increases — including moves by Deutsche Bank, Raymond James, Cantor Fitzgerald, and Baird — signals improving sentiment around medical cost trends and margin recovery.

What Could Prevent the Target From Being Reached

  • Margin execution risk: The 3%-by-2028 goal is ambitious; any slippage in medical loss ratios or cost transformation could stall the repricing.
  • Regulatory and coding scrutiny: Ongoing government attention to Medicare Advantage coding, rates, and Star Ratings methodology remains a persistent overhang.
  • Valuation: At roughly 39 times trailing earnings, Humana trades well above sector peers, leaving little cushion if sentiment cools.
  • Membership decline: The deliberate exit of lower-margin plans could pressure near-term revenue growth and add transition risk.

Technical Levels and Market Structure

Humana's 52-week high of $456.50, set in early October, is the most important resistance level between the current price and the $465 target — a decisive break above it would be a notable technical signal. Below the market, the recent pullback found support in the $409-to-$411 zone, with the psychologically important $400 level the next area of interest. The long-term structure is constructive after a rebound from the $163 low, but the sharp year-to-date advance leaves the stock vulnerable to profit-taking at new highs.

Time Horizon and What Investors Should Monitor

Analyst price targets typically reflect a roughly 12-month research horizon, though individual assumptions vary widely given the divergence in the $280-to-$596 range. The most consequential near-term events are the November 6, 2026 third-quarter earnings release and any update to full-year guidance; the Centers for Medicare & Medicaid Services rate and Stars developments; medical cost trend data; analyst estimate revisions; and progress on the CenterWell joint venture and the Medicare Advantage membership transition. No specific timing for reaching $465 should be assumed.

AI Daily Buy/Sell Signals

Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile, sentiment-sensitive name like Humana, the tool can help traders surface emerging opportunities, track existing positions, and identify shifting trends more efficiently than manual review. Traders can explore the signals to complement their own research on HUM and the broader managed-care sector.

Final Assessment

The $465 central target — the average of current analyst price targets spanning roughly $280 to $596 — implies a modest 12% move from the latest close near $414.50. The bull case rests on a genuine Star Ratings turnaround, reinstated bonus revenue, and a credible multiyear margin plan, reinforced by a recent run of upgrades. The bear case emphasizes an elevated valuation, execution uncertainty, and regulatory exposure. Given the unusually wide analyst dispersion, investors should treat $465 as a midpoint of informed opinion rather than a precise forecast, and watch the November earnings report and margin trends as the key tests of the thesis.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

View a ticker or compare two or three
Interact to see
Advertisement

HUM and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, HUM has been closely correlated with UNH. These tickers have moved in lockstep 71% of the time. This A.I.-generated data suggests there is a high statistical probability that if HUM jumps, then UNH could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HUM
1D Price
Change %
HUM100%
-1.50%
UNH - HUM
71%
Closely correlated
-5.55%
ELV - HUM
60%
Loosely correlated
-2.66%
CVS - HUM
53%
Loosely correlated
-1.61%
CNC - HUM
51%
Loosely correlated
-2.77%
MOH - HUM
37%
Loosely correlated
-1.56%
More

Groups containing HUM

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HUM
1D Price
Change %
HUM100%
-1.50%
HUM
(2 stocks)
93%
Closely correlated
+2.73%
Can Humana (HUM) Stock Reach $465?